EUVIMEDEUVIMED entdecken
Open Access

Pharmacokinetics, mass balance, and metabolism of [14C]SAF-189s, a potent anaplastic lymphoma kinase/c-ROS proto-oncogene 1 inhibitor in humans: Metabolism potentially affected by interaction of cytochrome P450 enzymes and intestinal microbiota

Ming Yang, Lei Diao, Shu Yan, Yan Tan, Donghui Liu, Yali Yuan, Zijian Zeng, Tao Hu, Dafang Zhong, Liyan Miao, Xingxing Diao

Drug Metabolism and Disposition · 2025

DOI: 10.1016/j.dmd.2025.100131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Ming Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China; Shanghai Center for Drug Metabolism and Pharmacokinetics, S…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Anaplastic Lymphoma Kinase, Cytochrome P-450 Enzyme System, Protein-Tyrosine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SAF-189s is a promising highly selective, brain-penetrant, next-generation inhibitor of anaplastic lymphoma kinase (ALK) and c-ROS proto-oncogene 1 (ROS1). The pharmacokinetics, mass balance, and metabolism of SAF-189s were measured in 6 healthy Chinese male participants after receiving a single oral dose of 160 mg [14C]SAF-189s (150 μCi). SAF-189s was rapidly absorbed with a median Tmax of 4.0 hours. The arithmetic mean half-life of total radioactivity in plasma was approximately 32.1 hours. The ratio of mean total drug-related substance concentration in whole blood to that in plasma (B/PAUC) was 3.06, indicating that the drug was predominantly distributed in blood cells. After 336 hours of drug administration, the average cumulative excretion of radioactivity accounted for 96.98% of the total dose, with 6.24% of the drug excreted in urine and 90.74% of the drug excreted in feces. In total, 14 metabolites were identified. SAF-189s was the predominant component in plasma but was scarcely detected in urine and feces. Oxidative metabolism mediated by CYP3A4 was determined to be the primary metabolic pathway for SAF-189s, with the isopropyl group being the most susceptible metabolizing site. M543 was identified as the main oxidative metabolite of SAF-189s in humans, and its production was likely affected by both CYP3A and intestinal microbiota. After a single oral dose of [14C]SAF-189s, SAF-189s and its principal metabolites were primarily excreted via feces. The main metabolic pathway was oxidation, likely catalyzed by both CYP3A and intestinal microbiota. SIGNIFICANCE STATEMENT: This study investigated the absorption and disposition of SAF-189s, a promising next-generation inhibitor of ALK/ROS1 administered for the treatment of ALK+/ROS1+ non-small cell lung cancer. The results demonstrated that SAF-189s and its metabolites were primarily excreted via feces, with metabolism likely mediated by both the cytochrome P450 system and gut microbiota. These findings provide essential pharmacokinetic and safety data, encourage further studies on drug interactions and dose adjustments, and support the involvement of gut microbiota, thereby guiding future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeAnaplastic Lymphoma KinaseCytochrome P-450 Enzyme SystemProtein-Tyrosine KinasesProto-Oncogene ProteinsProtein Kinase InhibitorsHumansMaleProto-Oncogene MasAdultCarbon RadioisotopesYoung AdultAdministration, OralHalf-LifeCytochrome P-450 CYP3ADrug InteractionsHealthy Volunteers

Stichwörter der Autor:innen

ALK/ROS1 inhibitorIntestinal floraNon–small cell lung cancerP450 enzymesSAF-189s metabolism and pharmacokinetics[(14)C]SAF-189s

Substanzen

Proto-Oncogene MasMAS1 protein, humanAnaplastic Lymphoma KinaseCytochrome P-450 Enzyme SystemProtein-Tyrosine KinasesProto-Oncogene ProteinsCarbon RadioisotopesProtein Kinase InhibitorsROS1 protein, humanCytochrome P-450 CYP3A

Autor:innen und Institutionen

  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China; Shanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shan…
  • Clinical Research Department, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Shanghai, China.
  • Shanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Department of Clinical Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, China; Institute for Interdisciplinary Drug Research and Translational Sciences, Soochow University, Suzhou, China.
  • Department of Clinical Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, China; Institute for Interdisciplinary Drug Research and Translational Sciences, Soochow University, Suzhou, China. Elect…

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Yang, M., Diao, L., Yan, S., Tan, Y., Liu, D., Yuan, Y., Zeng, Z., Hu, T., Zhong, D., Miao, L., & Diao, X. (2025). Pharmacokinetics, mass balance, and metabolism of [14C]SAF-189s, a potent anaplastic lymphoma kinase/c-ROS proto-oncogene 1 inhibitor in humans: Metabolism potentially affected by interaction of cytochrome P450 enzymes and intestinal microbiota. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100131

Vancouver

Yang M, Diao L, Yan S, Tan Y, Liu D, Yuan Y, et al. Pharmacokinetics, mass balance, and metabolism of [14C]SAF-189s, a potent anaplastic lymphoma kinase/c-ROS proto-oncogene 1 inhibitor in humans: Metabolism potentially affected by interaction of cytochrome P450 enzymes and intestinal microbiota. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100131

BibTeX
@article{Yang2025,
  author = {Yang, Ming and Diao, Lei and Yan, Shu and Tan, Yan and Liu, Donghui and Yuan, Yali and Zeng, Zijian and Hu, Tao and Zhong, Dafang and Miao, Liyan and Diao, Xingxing},
  title = {Pharmacokinetics, mass balance, and metabolism of [14C]SAF-189s, a potent anaplastic lymphoma kinase/c-ROS proto-oncogene 1 inhibitor in humans: Metabolism potentially affected by interaction of cytochrome P450 enzymes and intestinal microbiota},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  doi = {10.1016/j.dmd.2025.100131}
}
Kostenlos starten →